Matthew Sleeman is the VP of the Immunology & Inflammation group at Regeneron. His team supports the development of novel biologic therapies for the treatment of a range of different allergic and autoimmune diseases, such as atopic dermatitis, asthma and rheumatoid arthritis. In addition his group also works in immuno-oncology to develop new therapeutic approaches for cancer. This team has successfully supported the development of a number of Regenerons approved therapies, such as Dupixent (AntiIL4R), Kevzara (AntiIL6R) and Libtayo (antiPD1). Prior to joining Regeneron Matt Sleeman was a Senior Director of Biology for the Respiratory, Inflammation and Autoimmunity Group at MedImmune in Cambridge UK and also held several positions within Cambridge Antibody Technology (CAT). During this time he collaborated with CSL, the Walter and Eliza Hall Institute and the University of Melbourne working on the GM-CSF pathway, ultimately leading to the generation and development of the GM-CSFRa antibody mavrilimumab. Before working in the antibody field, he worked for a New Zealand start up Genesis Research & Development isolating and characterizing novel growth factors and cytokines. Matt Sleeman holds a PhD from the University of Durham, UK.